Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Faeth Therapeutics Inc., 3 years.
Faeth Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Faeth Therapeutics Inc. June 11, 202482.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 1, 2026 | Faeth Therapeutics Inc. | Open-market sale | −24,524 | $20.00 | $490,480 |
| Jun 1, 2026 | Faeth Therapeutics Inc. | Open-market sale | −476 | $21.14 | $10,063 |
| Dec 9, 2025 | Faeth Therapeutics Inc. | Open-market sale | −2,666 | $7.95 | $21,195 |
| Dec 9, 2025 | Faeth Therapeutics Inc. | Option exercise | +395 | $6.40 | $2,528 |
| Dec 9, 2025 | Faeth Therapeutics Inc. | Open-market sale | −395 | $8.04 | $3,176 |
| Dec 9, 2025 | Faeth Therapeutics Inc. | Open-market sale | −446 | $7.92 | $3,532 |
| Dec 8, 2025 | Faeth Therapeutics Inc. | Open-market sale | −3,105 | $8.59 | $26,672 |
| Dec 5, 2025 | Faeth Therapeutics Inc. | Open-market sale | −14,508 | $11.40 | $165,391 |
| Dec 5, 2025 | Faeth Therapeutics Inc. | Open-market sale | −1,745 | $12.29 | $21,446 |
| Dec 5, 2025 | Faeth Therapeutics Inc. | Open-market sale | −42 | $13.16 | $553 |
| Dec 4, 2025 | Faeth Therapeutics Inc. | Open-market sale | −5,000 | $9.06 | $45,300 |
| Jul 31, 2023 | Faeth Therapeutics Inc. | Sold back to the company | −1,587,302 | $1.26 | $2,000,001 |
| Jul 10, 2023 | Faeth Therapeutics Inc. | Grant or award | +4,466 | — | — |
Questions about James Peyer
What boards is James Peyer on?
James Peyer sits on the board of Faeth Therapeutics Inc.
How long has James Peyer served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.